Protagenic Therapeutics (NASDAQ: PTIX) has secured $3.1 million in funding through warrant exchanges and exercises over a four-day trading period. The company plans to utilize these proceeds for working capital requirements and to advance its development of peptide-based drug candidates targeting stress-related and central nervous system disorders. This financial development follows Protagenic's recently announced business combination with Phytanix Bio Inc. on May 19, 2025, which has consolidated six complementary drug development programs focusing on stress disorders, epilepsy, obesity, and other indications under a single entity.
Protagenic Therapeutics (NASDAQ: PTIX) ha ottenuto 3,1 milioni di dollari di finanziamento tramite scambi ed esercizi di warrant in un periodo di quattro giorni di contrattazioni. L'azienda intende utilizzare questi fondi per esigenze di capitale circolante e per avanzare nello sviluppo di candidati farmaceutici peptidici mirati a disturbi legati allo stress e al sistema nervoso centrale. Questo sviluppo finanziario segue la recente fusione annunciata da Protagenic con Phytanix Bio Inc. il 19 maggio 2025, che ha unito sei programmi complementari di sviluppo farmaceutico focalizzati su disturbi da stress, epilessia, obesit脿 e altre indicazioni sotto un'unica entit脿.
Protagenic Therapeutics (NASDAQ: PTIX) ha asegurado 3,1 millones de d贸lares en financiamiento mediante intercambios y ejercicios de warrants durante un per铆odo de cuatro d铆as de negociaci贸n. La compa帽铆a planea utilizar estos fondos para necesidades de capital de trabajo y para avanzar en el desarrollo de candidatos a f谩rmacos pept铆dicos dirigidos a trastornos relacionados con el estr茅s y el sistema nervioso central. Este avance financiero sigue a la reciente combinaci贸n empresarial anunciada por Protagenic con Phytanix Bio Inc. el 19 de mayo de 2025, que ha consolidado seis programas complementarios de desarrollo farmac茅utico enfocados en trastornos de estr茅s, epilepsia, obesidad y otras indicaciones bajo una sola entidad.
Protagenic Therapeutics (NASDAQ : PTIX) a obtenu un financement de 3,1 millions de dollars gr芒ce 脿 des 茅changes et exercices de bons de souscription sur une p茅riode de quatre jours de bourse. La soci茅t茅 pr茅voit d'utiliser ces fonds pour ses besoins en fonds de roulement et pour faire avancer le d茅veloppement de ses candidats-m茅dicaments 脿 base de peptides ciblant les troubles li茅s au stress et au syst猫me nerveux central. Cette avanc茅e financi猫re fait suite 脿 la r茅cente annonce de la fusion d'entreprise entre Protagenic et Phytanix Bio Inc. le 19 mai 2025, qui a regroup茅 six programmes compl茅mentaires de d茅veloppement pharmaceutique ax茅s sur les troubles du stress, l'茅pilepsie, l'ob茅sit茅 et d'autres indications sous une m锚me entit茅.
Protagenic Therapeutics (NASDAQ: PTIX) hat innerhalb eines vier Handelstage umfassenden Zeitraums 3,1 Millionen US-Dollar an Finanzierung durch Warrant-Umtausch und -Aus眉bung erhalten. Das Unternehmen plant, diese Mittel f眉r den Betriebskapitalbedarf zu verwenden und die Entwicklung von peptidbasierten Arzneimittelkandidaten voranzutreiben, die auf stressbedingte und zentrale Nervensystem-Erkrankungen abzielen. Diese finanzielle Entwicklung folgt auf die k眉rzlich bekannt gegebene Unternehmenszusammenf眉hrung von Protagenic mit Phytanix Bio Inc. am 19. Mai 2025, durch die sechs sich erg盲nzende Arzneimittelentwicklungsprogramme zu Stressst枚rungen, Epilepsie, Fettleibigkeit und weiteren Indikationen unter einem Dach geb眉ndelt wurden.
Positive
Raised $3.1 million in capital through warrant activities
Strategic business combination with Phytanix Bio expanding drug pipeline to six programs
Diversified portfolio spanning multiple therapeutic areas
Negative
Dilution of existing shares through warrant exercises
Additional capital may be needed for multiple drug development programs
NEW YORK, NY / / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
This financing comes as Protagenic executes on its previously announced business combination with Phytanix Bio Inc. (May 19, 2025). The combination has brought together six complementary drug programs spanning stress disorders, epilepsy, obesity, and other indications under one company.
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics (Nasdaq: PTIX) is pioneering peptides for stress-related disorders. For more information, visit .
About Phytanix Bio Inc.
Phytanix Bio is an innovative pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and "cannabinoid-like" molecules. For more information, visit .
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
Company Contact:
Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010 Tel: 213-260-4342 Email: [email protected]
SOURCE: Protagenic Therapeutics, Inc.
View the original on ACCESS Newswire
FAQ
How much funding did PTIX raise through warrant activity in May 2025?
Protagenic Therapeutics (PTIX) raised $3.1 million through warrant exchanges and exercises over four trading days in May 2025.
What will PTIX use the $3.1 million warrant proceeds for?
The proceeds will be used for working capital needs and to advance the company's peptide-based drug candidates for stress-related and central nervous system disorders.
When did PTIX announce its business combination with Phytanix Bio?
Protagenic Therapeutics announced its business combination with Phytanix Bio Inc. on May 19, 2025.
What therapeutic areas are included in PTIX's drug development pipeline after the Phytanix merger?
The combined company's pipeline includes six drug programs targeting stress disorders, epilepsy, obesity, and other indications.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
